|
|
Upcoming
Past
- Oncologic Drugs Advisory Committee,
September 6-7, 2006, Silver Spring, MD. Federal Register notice [TXT]
[PDF]
The following NDAs will be discussed:
- NDA 21-874,
proposed trade name GENASENSE (oblimersen
sodium) Injection, Genta, Inc., proposed
indication for the treatment of patients
with chronic lymphocytic leukemia in
combination with fludarabine and
cyclophosphamide
- NDA 020-287,
FRAGMIN (dalteparin sodium), Pfizer,
Inc., proposed indication for the extended
treatment of symptomatic venous
thromboembolism (VTE), proximal deep vein
thrombosis, and/or pulmonary embolism to
reduce the recurrence of VTE in
patients with cancer.
- NDA 21-660,
ABRAXANE (paclitaxel protein-bound
particles for injectible suspension)
(albumin-bound), Abraxis Bioscience, Inc.,
including trial design issues for adjuvant
treatment of node-positive breast cancer.
- Ovarian Cancer Endpoints - FDA and the American Society of Clinical Oncology (ASCO), with
co-sponsorship by the American Association for Cancer Research (AACR), April 26, 2006,
8:00 to 5:00 pm, North Bethesda, Maryland.
Meeting Information
- 2003-2006:
Meetings for cancer endpoints for primary
brain tumors, lung cancer, colorectal
cancer, prostate cancer, and acute leukemia.
Meeting Information
-
Past Oncologic Drug Advisory Committee
Meetings
|
|